Drug Profile
Research programme: Huntington's disease therapeutics - Ionis Pharmaceuticals/Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals; Roche
- Developer Ionis Pharmaceuticals; Roche
- Class Antisense oligonucleotides
- Mechanism of Action HD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Huntington's-disease in Switzerland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Huntington's-disease in USA (Parenteral)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals